Loading...
•
Mar 31, 2021
Mimedx Q1 2021 Earnings Report
MiMedx's first quarter performance in 2021 reflected advancements in clinical programs and core business growth.
Key Takeaways
MiMedx Group, Inc. reported net sales of $60.0 million for Q1 2021, a slight decrease compared to $61.7 million in the prior year. The company is progressing with its late-stage clinical programs and expanding its field personnel.
Completed final clinical visits in Phase 3 studies for Plantar Fasciitis and Achilles Tendonitis.
Announced completion of clinical effectiveness endpoint visits in a Phase 2B study for Knee Osteoarthritis.
Appointed Dirk Stevens as Senior Vice President, Quality Assurance and Regulatory Affairs.
Received FDA acceptance for the IND of AmnioFix® Injectable in Chronic Cutaneous Ulcers.
Forward Guidance
MiMedx anticipates that adjusted net sales for 2021 will align with the previous year due to the conclusion of the Enforcement Discretion period on May 31, 2021.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...